Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | DDX3X | O00571 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28433481 | 0.86 | DDX3X (0.62) | LMNACXCR1CXCR2MAPTALDH1A1 | |
| SCHEMBL11332310 | 0.82 | KMT2A (0.73) | L3MBTL1LMNACXCR1CXCR2MAPT | |
| SCHEMBL6501234 | 0.82 | MEN1 (0.59) | LMNACXCR1CXCR2MAPTALDH1A1 | |
| SCHEMBL6500776 | 0.80 | DDX3X (0.64) | LMNACXCR2MAPTSMN1; SMN2NPC1 | |
| SCHEMBL33666 | 0.79 | TDP1 (1.00) | TDP1L3MBTL1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1585523 | 0.79 | TDP1 (1.00) | TDP1L3MBTL1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL5180325 | 0.78 | ALDH1A1 (0.55) | TDP1L3MBTL1LMNAMAPTALDH1A1 | |
| SCHEMBL4388940 | 0.78 | CXCR2 (0.78) | TDP1L3MBTL1LMNACXCR1CXCR2 | |
| SCHEMBL1554424 | 0.78 | TDP1 (0.63) | TDP1L3MBTL1LMNACXCR1CXCR2 | |
| SCHEMBL175272 | 0.77 | MEN1 (0.71) | TDP1L3MBTL1LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960599-B2 | Heterocyclic aminoalkylpyridine derivatives as psychopharmaceuticals | MERCK PATENT GMBH (DE) | 2005-11-01 | — | — | US | claimed |
| US-20040019044-A1 | Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals | MERCK PATENT GMBH (DE) | 2004-01-29 | — | — | US | claimed |
| US-6960599-B2 | Heterocyclic aminoalkylpyridine derivatives as psychopharmaceuticals | MERCK PATENT GMBH (DE) | 2005-11-01 | — | — | US | disclosed |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | disclosed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | disclosed |
| US-6380189-B1 | FOR TREATING HERPES-RELATED DISORDERS | G.D. SEARLE & CO. | 2002-04-30 | — | — | US | disclosed |
| EP-0828721-B1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | SEARLE & CO (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1122245-A2 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. Searle & Co. (US) | 2001-08-08 | — | — | EP | disclosed |
| US-5985872-A | THERAPEUTIC TREATMENT OF HERPES VIRAL INFECTION | G.D. SEARLE & CO. (US) | 1999-11-16 | — | — | US | disclosed |
| CN-1190963-A | 2-amino-benzoxanones for the treatment of viral infections | SEARLE & CO (US) | 1998-08-19 | — | — | CN | disclosed |
| EP-0828721-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037485-A1 | 2-AMINO-BENZOXAZINONES FOR THE TREATMENT OF VIRAL INFECTIONS | G.D. SEARLE & CO. (US) | 1996-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | TDP1 2851/4885L3MBTL1 2672/4885LMNA 2849/4885 |
| US-20050032793-A1 | 2-amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, ACE2 | TDP1 2946/4885L3MBTL1 2622/4885LMNA 2211/4885 |
| US-20040019044-A1 | Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals | HTR4, CNR1, CNR2 | TDP1 3233/4885L3MBTL1 3893/4885LMNA 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.